文献速递胸部肿瘤

肺腺癌向小细胞癌转化的克隆历史与遗传预测因素

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
PubMed 文献 · J Clin Oncol · 2017-05-12

该研究纳入21例EGFR突变肺腺癌经EGFR酪氨酸激酶抑制剂(TKI)治疗后转化为小细胞肺癌的患者,对其中4例的9份不同时间点肿瘤行全基因组测序重建克隆演化史,并在210份肺癌组织中验证。结果显示转化前后肿瘤共享克隆起源、早期分支演化,RB1与TP53双失活可预测小细胞转化。

要点

  • EGFR TKI耐药肺腺癌与小细胞肺癌共享克隆起源,呈分支演化轨迹。
  • 小细胞癌祖先的克隆分歧发生在首次EGFR TKI治疗之前。
  • 早期肺腺癌中RB1与TP53双失活可预测后续小细胞转化。

核心结论

  • EGFR TKI耐药的小细胞肺癌早期即从携带RB1和TP53完全失活的肺腺癌克隆分支而出。
  • 评估EGFR TKI治疗肺腺癌的RB1和TP53状态有助于预测小细胞转化。

研究设计与样本

  • 研究纳入21例经EGFR TKI治疗后转化为耐药小细胞肺癌的晚期EGFR突变肺腺癌患者。
  • 对4例患者的9份不同时间点获取的肿瘤行全基因组测序,重建克隆演化史并检测小细胞转化的遗传预测因素。
  • Findings在210份肺癌组织中通过免疫组化验证。

主要发现

  • EGFR TKI耐药的肺腺癌与小细胞肺癌共享克隆起源,呈分支演化轨迹。
  • 小细胞癌祖先与肺腺癌细胞的克隆分歧发生在首次EGFR TKI治疗之前,测序肿瘤中早期肺腺癌阶段即观察到RB1和TP53双完全失活。
  • 在75例接受EGFR TKI治疗的早期肺腺癌组织中,小细胞转化组Rb和p53双失活显著更常见(82% vs 3%;比值比131;95%CI 19.9至859)。
  • 在预设队列(n=65)中,携带Rb和p53完全失活的EGFR突变肺腺癌发生小细胞转化的风险为42.8倍(相对危险度42.8;95%CI 5.88至311)。
  • 分支特异性突变特征分析显示,APOBEC诱导的超突变在小细胞转化分支中频繁出现。

关键数值与推荐

  • 小细胞转化组Rb和p53双失活频率82% vs 非转化组3%(比值比131;95%CI 19.9至859)。
  • 预设队列(n=65)中Rb和p53完全失活的EGFR突变肺腺癌小细胞转化相对危险度42.8(95%CI 5.88至311)。

临床怎么用

  • 作者认为,评估EGFR TKI治疗肺腺癌的RB1和TP53状态有助于预测小细胞转化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Histologic transformation of EGFR mutant lung adenocarcinoma (LADC) into small-cell lung cancer (SCLC) has been described as one of the major resistant mechanisms for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, the molecular pathogenesis is still unclear. Methods We investigated 21 patients with advanced EGFR-mutant LADCs that were transformed into EGFR TKI-resistant SCLCs. Among them, whole genome sequencing was applied for nine tumors acquired at various time points from four patients to reconstruct their clonal evolutionary history and to detect genetic predictors for small-cell transformation. The findings were validated by immunohistochemistry in 210 lung cancer tissues. Results We identified that EGFR TKI-resistant LADCs and SCLCs share a common clonal origin and undergo branched evolutionary trajectories. The clonal divergence of SCLC ancestors from the LADC cells occurred before the first EGFR TKI treatments, and the complete inactivation of both RB1 and TP53 were observed from the early LADC stages in sequenced tumors. We extended the findings by immunohistochemistry in the early-stage LADC tissues of 75 patients treated with EGFR TKIs; inactivation of both Rb and p53 was strikingly more frequent in the small-cell-transformed group than in the nontransformed group (82% v 3%; odds ratio, 131; 95% CI, 19.9 to 859). Among patients registered in a predefined cohort (n = 65), an EGFR mutant LADC that harbored completely inactivated Rb and p53 had a 43× greater risk of small-cell transformation (relative risk, 42.8; 95% CI, 5.88 to 311). Branch-specific mutational signature analysis revealed that apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)-induced hypermutation was frequent in the branches toward small-cell transformation. Conclusion EGFR TKI-resistant SCLCs are branched out early from the LADC clones that harbor completely inactivated RB1 and TP53. The evaluation of RB1 and TP53 status in EGFR TKI-treated LADCs is informative in predicting small-cell transformation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JK, Lee J, Kim S, et al. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. J Clin Oncol. 2017. PMID: 28498782. doi:10.1200/JCO.2016.71.9096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。